Novo Nordisk may have ignited the weight-loss drug frenzy with Ozempic, but Eli Lilly is hot on its heels, aiming to dominate this lucrative market. However, the company faces significant hurdles on its path to pharmaceutical dominance. The demand for Eli Lilly’s weight-loss drugs, particularly Mounjaro and Zepbound, is skyrocketing. With an estimated 100 million Americans and 1 billion individuals…